Article

Chimerism and Tolerance Without GVHD or Engraftment Syndrome in HLA-Mismatched Combined Kidney and Hematopoietic Stem Cell Transplantation

Comprehensive Transplant Center, Northwestern Memorial Hospital, Chicago, IL 60611, USA.
Science translational medicine (Impact Factor: 15.84). 03/2012; 4(124):124ra28. DOI: 10.1126/scitranslmed.3003509
Source: PubMed

ABSTRACT

The toxicity of chronic immunosuppressive agents required for organ transplant maintenance has prompted investigators to pursue approaches to induce immune tolerance. We developed an approach using a bioengineered mobilized cellular product enriched for hematopoietic stem cells (HSCs) and tolerogenic graft facilitating cells (FCs) combined with nonmyeloablative conditioning; this approach resulted in engraftment, durable chimerism, and tolerance induction in recipients with highly mismatched related and unrelated donors. Eight recipients of human leukocyte antigen (HLA)-mismatched kidney and FC/HSC transplants underwent conditioning with fludarabine, 200-centigray total body irradiation, and cyclophosphamide followed by posttransplant immunosuppression with tacrolimus and mycophenolate mofetil. Subjects ranged in age from 29 to 56 years. HLA match ranged from five of six loci with related donors to one of six loci with unrelated donors. The absolute neutrophil counts reached a nadir about 1 week after transplant, with recovery by 2 weeks. Multilineage chimerism at 1 month ranged from 6 to 100%. The conditioning was well tolerated, with outpatient management after postoperative day 2. Two subjects exhibited transient chimerism and were maintained on low-dose tacrolimus monotherapy. One subject developed viral sepsis 2 months after transplant and experienced renal artery thrombosis. Five subjects experienced durable chimerism, demonstrated immunocompetence and donor-specific tolerance by in vitro proliferative assays, and were successfully weaned off all immunosuppression 1 year after transplant. None of the recipients produced anti-donor antibody or exhibited engraftment syndrome or graft-versus-host disease. These results suggest that manipulation of a mobilized stem cell graft and nonmyeloablative conditioning represents a safe, practical, and reproducible means of inducing durable chimerism and donor-specific tolerance in solid organ transplant recipients.

Download full-text

Full-text

Available from: Lorenzo Gallon, Dec 13, 2014
  • Source
    • "Des greffé s ré naux ont reçu aussi de leur donneur d'organes des cellules souches de la moelle osseuse, pré curseurs des cellules immunitaires, dans le but que le rein du donneur soit reconnu comme faisant partie de l'organisme du receveur. Aprè s avoir colonisé la moelle osseuse des patients, les cellules souches engendrent des cellules immunitaires apparenté es au donneur, donc au rein greffé , et facilitent l'acceptation de cet organe au point d'arrêter tout traitement immunosuppresseur quelques mois aprè s la greffe [29] "
    [Show abstract] [Hide abstract]
    ABSTRACT: First kidney transplant attempts begin with the 20th century: improving vascular sutures, understanding the phenomena of rejection or tolerance, then progress in HLA groups enable early success in the second half of the century. Definition of brain death, use of corticosteroids, radiotherapy and prime immunosuppressors promote the development of transplants. Discover of cyclosporine in the 1980s, and legislative developments augur a new era. Many advances are arising: use of stem cells from the donor, enhancement of Maastricht 3 donor or living donation. Finally organ transplantation remains an immense human adventure, but also scientific and ethic. Copyright © 2015 Association Société de néphrologie. Published by Elsevier SAS. All rights reserved.
    Full-text · Article · Jul 2015 · Néphrologie & Thérapeutique
  • Source
    • "Kawai et al. (2013) showed that combined bone marrow and kidney transplants from HLA single haplotype mismatched living donors resulted in mixed chimerism and donor unresponsiveness in four out of five patients, facilitating withdrawal of immunosuppression . Leventhal et al. (2012) showed mobilized stem cell graft and nonmyeloablative conditioning induces durable chimerism and donor-specific tolerance in solid organ transplant recipients. Leucocyte depletion with alemtuzumab has been shown to induce tolerance in Campath1-H pilot study (Trzonkowski et al., 2008). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The 3rd International Transplant Conference took place on 31st October and 1st November 2014 at the University of Warwick, Coventry, UK. Key focal points of the meeting were the exploration of the molecular basis of antibody-antigen interactions and their relation to clinical practice and to share experiences and knowledge regarding strategies to transplant the 'high-risk' patient. In addition, lively debate sessions were hosted where controversial clinical and immunological themes were discussed by leading experts in the field. © 2015 John Wiley & Sons Ltd.
    Full-text · Article · Feb 2015 · International Journal of Immunogenetics
  • Source
    • "Hematopoietic chimerism is another attractive therapeutic option to induce allograft tolerance and therefore eliminate or minimize TV related to chronic rejection. This has been successfully accomplished in animal models undergoing heart transplantation and in human models undergoing renal transplantation [Pasquet et al., 2011, 2013; Leventhal et al., 2012, 2013; Yamada et al., 2012; Kawai and Sachs, 2013]. Advances in regenerative tissue engineering using autologous stem or progenitor cells hold great potential to create a bioartifical heart [Taylor, 2009]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Remarkable achievements have been made in the clinical application of mechanical circulatory support and cardiac transplantation for patients with end-stage heart failure. Despite the successes, complications associated with these therapies continue to drive cardiac regenerative research utilizing stem cell based therapies. Multiple stem cell lineages hold clinical promise for cardiac regeneration—mostly through cellular differentiation, cellular fusion, and paracrine signaling mechanisms. Bone marrow-derived endothelial progenitor cells are among the most intriguing and controversial cell types currently being investigated. Formidable barriers exist, however, in finding the ideal cardiac regenerative stem cell, such as identifying specific lineage markers, optimizing in vitro cellular expansion and improving methods of stem cell delivery. Hybrid approaches of cardiac regeneration using stem cell therapies in conjunction with immunomodulation after cardiac transplantation or with mechanical circulatory support produce cutting edge stem cell technologies. This review summarizes the current knowledge and therapeutic applications of stem cells in patients with end-stage heart failure, including stem cell therapy after implantation of mechanical circulatory support and cardiac transplantation. J. Cell. Biochem. © 2013 Wiley Periodicals, Inc.
    Full-text · Article · Jul 2014 · Journal of Cellular Biochemistry
Show more